The seed round was co-led by kyu Collective and Global Ventures to support product and partnership growth.
"We’re proud to announce Neol’s successful seed funding round. To receive backing from such esteemed VC firms and angel investors is a massive testament to our business strategy and vision. At Neol, we believe creative individuals are the core to driving meaningful growth in the world. And we will be relentlessly building Neol to be the platform where they can connect, learn and shape while also participating as owners of the very platform they are part of."
Parkwalk led the Series B financing, with participation from Meltwind, Newable Ventures and BGF, to widen access to the Censeo platform.
"The continued support from Parkwalk, Meltwind and BGF alongside new investment from Newable Ventures enables us to expand the reach of Censeo, helping more people who are struggling to find the right support for their mental health needs. We’re excited to grow our team, expand further across the NHS and demonstrate with our partners that our technology can make a substantial difference in the accuracy, consistency and efficiency of mental health assessments in a wide range of clinical settings."
LDC has agreed to make a significant investment in the audience-first advertising platform.
"I’m proud of everything we achieved in the past 18 years, and I’m looking forward to accelerating our growth plans in partnership with LDC. We have an incredibly dedicated and passionate team focused on the company’s growth and ready to help the industry move forward in the right direction. LDC believes in our promise as the audience-first platform that doesn’t rely on personal data, and their unparalleled expertise will, undoubtedly, help Blis to continue expanding globally."
The Series B round was led by Autodesk with backing from Lockheed Martin and British Patient Capital.
"When people think of manufacturing, they tend to think of robotic car factories, and don’t realise that the industry is dominated by craft processes reliant on dwindling expert knowledge. This makes it incredibly complex to get things made, stifling the pace of innovation,"
Kester Capital provides further backing to accelerate the development of computer-aided drug discovery technologies.
"It’s been an incredible year, with Kester Capital’s original investment affording us the opportunity to take the company to new heights as we successfully launched Cerella, our ground-breaking new AI platform, and actioned ambitious plans to grow the company. I am delighted that due to this success, Kester is investing further and their continued support will allow us to accelerate our product development plans and further capitalise on the substantial market opportunities."
.png)
